Orum Therapeutics (475830) Fundamentals 2026 — Revenue Analysis | SniperIQ
Orum Therapeutics (475830) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩901.3B, trading at ₩42450.00 on the KOE. This SniperIQ fundamentals page covers Orum Therapeutics's valuation, profitability (net margin -104129439.0%), revenue (₩24M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Orum Therapeutics's market cap?
Orum Therapeutics (475830) has a market capitalization of approximately ₩901.3B, trading at ₩42450.00 on the KOE. Market cap moves with the live share price.
What is Orum Therapeutics's P/E ratio?
Orum Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Orum Therapeutics?
Orum Therapeutics runs a net profit margin of -104129439.0%, a gross margin of -5659393.5%, and an operating margin of -123201358.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Orum Therapeutics generate?
Orum Therapeutics reported revenue of ₩24M for fiscal year 2025, with net income of -₩42.0B and earnings per share (EPS) of -2016.61. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Orum Therapeutics pay a dividend?
Orum Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Orum Therapeutics financially healthy?
Orum Therapeutics carries a debt-to-equity ratio of 0.22x and a current ratio of 1.63x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Orum Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Orum Therapeutics (475830) the key facts are: market cap ₩901.3B, revenue ₩24M, 52-week range 20500-146600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Orum Therapeutics's full fundamentals live
Get Orum Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.